Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHINOME study
2026-527032-14-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tezepelumab in severe asthma, sponsored by Capital Region of Denmark. Primary endpoint: TSLP protein levels after poly(I:C) stimulation at baseline. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2026-527032-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527032-14-00.